新冠患者使用经鼻高流量氧疗:生物气溶胶扩散风险低
该文关注新冠低氧血症患者使用经鼻高流量氧疗(HFNC)时生物气溶胶扩散的风险。文中指出,HFNC 的生物气溶胶扩散风险与标准氧疗面罩相似;患者佩戴外科口罩时使用高流量鼻导管,可能使低氧血症新冠患者获益,且不增加环境风险。
要点
- HFNC 生物气溶胶扩散风险与标准氧疗面罩相似。
- 低氧血症新冠患者使用 HFNC 可改善氧合。
- 患者面部加戴外科口罩或可降低环境暴露风险。
核心结论
- 经鼻高流量氧疗的生物气溶胶扩散风险与标准氧疗面罩相似。
- 患者佩戴外科口罩时使用高流量鼻导管,可能使低氧血症新冠患者获益且不增加环境风险。
主要发现
- 在急性低氧性呼吸衰竭患者中,HFNC 相比传统氧疗设备可避免插管。
临床怎么用
- 新冠低氧血症患者可考虑 HFNC 改善氧合,并可在患者面部加戴外科口罩以兼顾环境安全。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bio-aerosol dispersion via high-flow nasal cannula shows a similar risk to standard oxygen masks. High-flow nasal prongs with a surgical mask on the patient's face might benefit hypoxaemic COVID-19 patients without added risk for the environment. https://bit.ly/34p7Fyy Human-to-human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission has been established, with >3300 clinicians reported to be infected in China and >1116 clinicians infected in Italy, where 13 882 cases were confirmed by 13 March 2020. Room surfaces in the vicinity of coronavirus disease 2019 (COVID-19) symptomatic patients and clinicians' protective equipment were found to be contaminated [1]. The primary strategy for COVID-19 patients is supportive care, including oxygen therapy for hypoxaemic patients, in which high-flow nasal cannula (HFNC) has been reported to be effective in improving oxygenation. Among patients with acute hypoxaemic respiratory failure, HFNC was proven to avoid intubation compared to conventional oxygen devices [2, 3].
引用
- Li J, Fink JB, Ehrmann S, et al. High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion. Eur Respir J. 2020. PMID: 32299867. doi:10.1183/13993003.00892-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。